Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus in neutropenic patients with cancer by Monte Carlo simulations

References

• Vicente M, Al-Nahedh M, Parsad S, Knoebel RW, Pisano J, Pettit NN. Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia. J Oncol Pharm Pract. 2017;23(8):575–81.
   PubMed Web of Science ®Google Scholar
• Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Therapeutic Adv Infection. 2013;1(6):183–90.
   PubMedGoogle Scholar
• Kosmidis CI, Chandrasekar PH. Management of gram-positive bacterial infections in patients with cancer. Leuk Lymphoma. 2012;53(1):8–18.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56-93.
   PubMed Web of Science ®Google Scholar
• Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia－a cause for concern. Support Care Cancer. 2008;16(9):1085–8.
   PubMed Web of Science ®Google Scholar
• Mahajan SN, Shah JN, Hachem R, Tverdek F, Adachi JA, Mulanovich V, et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist. 2012;17(10):1329–36.
   PubMed Web of Science ®Google Scholar
• He N, Dong F, Liu W, Zhai S. A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia. Infect Drug Resist. 2020;13:1807–21.
   PubMed Web of Science ®Google Scholar
• Haeseker MB, Croes S, Neef C, Bruggeman CA, Stolk LM, Verbon A. Vancomycin dosing in neutropenic patients. PLoS One. 2014;9(11):e112008.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43(6):405–15.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568–76.
   PubMed Web of Science ®Google Scholar
• Dong H, Xie J, Wang T, Chen L, Zeng X, Sun J, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. Int J Antimicrob Agents. 2016;48(3):259–64.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Tod M, Rizzo N, Padoin C, Biard O, Casassus P, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother. 1996;40(5):1242–7.
   PubMed Web of Science ®Google Scholar
• Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003; 14(5):795–801.
   PubMed Web of Science ®Google Scholar
• Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(2):428–34.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361–4.
   PubMed Web of Science ®Google Scholar
• Kontou A, Sarafidis K, Begou O, Gika HG, Tsiligiannis A, Ogungbenro K, et al. Population pharmacokinetics of teicoplanin in preterm and term neonates: Is it time for a new dosing regimen? Antimicrob Agents Chemother. 2020;64(4):e01971–19.
   PubMed Web of Science ®Google Scholar
• Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–23.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22(11):982–92.
   PubMed Web of Science ®Google Scholar
• Bury D, Ter Heine R, van de Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. Eur J Clin Pharmacol. 2019;75(7):921–8.
   PubMed Web of Science ®Google Scholar
• Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52(8):969–74.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734–44.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hiramatsu K, Suzuki Y, Tanaka R, Kaneko T, Nonoshita K, et al. Optimal trough concentration of teicoplanin in febrile neutropenic patients with hematological malignancy. Chemotherapy. 2018;63(1):29–34.
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kouranos VD, Christodoulou C, Falagas ME. Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? Expert Rev anti Infect Ther. 2009;7(4):415–22.
   PubMed Web of Science ®Google Scholar
• Abdel Hadi O, Al Omar S, Nazer LH, Mubarak S, Le J. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. J Oncol Pharm Pract. 2016;22(3):448–53.
   PubMed Web of Science ®Google Scholar
• Hahn-Ast C, Glasmacher A, Arns A, Mühling A, Orlopp K, Marklein G, et al. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant? Infection. 2008;36(1):54–8.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.
   PubMed Web of Science ®Google Scholar
• Ziglam HM, Gelly K, Olver W. A survey of the management of neutropenic fever in oncology units in the UK. Int J Antimicrob Agents. 2007;29(4):430–3.
   PubMed Web of Science ®Google Scholar
• Tai CH, Shao CH, Chen CY, Lin SW, Wu CC. Safety of high-dose daptomycin in patients with severe renal impairment. TCRM. 2018;Volume 14:493–9.
   Google Scholar
• Pea F. Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. J Infect Chemother. 2020;26(9):900–7.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568–74.
   PubMed Web of Science ®Google Scholar